Demonstration of specific plasma protein binding sites for somatomedin - PubMed (original) (raw)
Demonstration of specific plasma protein binding sites for somatomedin
R L Hintz et al. J Clin Endocrinol Metab. 1977 Nov.
Abstract
Native somatomedin (SM) has an apparent mol wt of at least 60,000 daltons, while all the purified SM peptides have mol wt 5-8,000 daltsons. We have studied the behavior of somatomedin in plasma during gel filtration at pH 8.1 and pH 2.8, and by the recombination of fractions. Using porcine bioassay for SM, displacement of 125I-insulin by SM, and binding of 125I-SM to plasma proteins, we can demonstrate that the disparity in apparent mol wt of SM is due to reversible binding to plasma proteins which are themselves biologically inactive. This binding site is specific for the SM peptides, saturable, and has high affinity and relatively low capacity.
Similar articles
- Isolation and partial characterization of six somatomedin-like peptides from human plasma Cohn fraction IV.
Blum WF, Ranke MB, Bierich JR. Blum WF, et al. Acta Endocrinol (Copenh). 1986 Feb;111(2):271-84. doi: 10.1530/acta.0.1110271. Acta Endocrinol (Copenh). 1986. PMID: 3953237 - Comparison of [125I]somatomedin A and [125I]somatomedin C radioreceptor assays for somatomedin peptide content in whole and acid-chromatographed plasma.
Horner JM, Liu F, Hintz RL. Horner JM, et al. J Clin Endocrinol Metab. 1978 Dec;47(6):1287-95. doi: 10.1210/jcem-47-6-1287. J Clin Endocrinol Metab. 1978. PMID: 263658 - Somatomedin peptide distribution and somatomedin-binding protein content in cord plasma: comparison to normal and hypopituitary plasma.
Borsi L, Rosenfeld RG, Liu F, Hintz RL. Borsi L, et al. J Clin Endocrinol Metab. 1982 Feb;54(2):223-8. doi: 10.1210/jcem-54-2-223. J Clin Endocrinol Metab. 1982. PMID: 6172441 - Plasma forms of somatomedin and the binding protein phenomenon.
Hintz RL. Hintz RL. Clin Endocrinol Metab. 1984 Mar;13(1):31-42. doi: 10.1016/s0300-595x(84)80007-9. Clin Endocrinol Metab. 1984. PMID: 6202446 Review. - Somatomedins and steroids.
Caufriez A, Copinschi G. Caufriez A, et al. Horm Res. 1986;24(2-3):185-8. doi: 10.1159/000180558. Horm Res. 1986. PMID: 3530941 Review.
Cited by
- Endocrine and cellular physiology and pathology of the insulin-like growth factor acid-labile subunit.
Baxter RC. Baxter RC. Nat Rev Endocrinol. 2024 Jul;20(7):414-425. doi: 10.1038/s41574-024-00970-4. Epub 2024 Mar 21. Nat Rev Endocrinol. 2024. PMID: 38514815 Review. - Pregnancy-Associated Plasma Protein (PAPP)-A2 in Physiology and Disease.
Barrios V, Chowen JA, Martín-Rivada Á, Guerra-Cantera S, Pozo J, Yakar S, Rosenfeld RG, Pérez-Jurado LA, Suárez J, Argente J. Barrios V, et al. Cells. 2021 Dec 18;10(12):3576. doi: 10.3390/cells10123576. Cells. 2021. PMID: 34944082 Free PMC article. Review. - Insulin-like growth factors: Ligands, binding proteins, and receptors.
LeRoith D, Holly JMP, Forbes BE. LeRoith D, et al. Mol Metab. 2021 Oct;52:101245. doi: 10.1016/j.molmet.2021.101245. Epub 2021 May 4. Mol Metab. 2021. PMID: 33962049 Free PMC article. Review. - Insulin-like growth factor system in cancer: novel targeted therapies.
Brahmkhatri VP, Prasanna C, Atreya HS. Brahmkhatri VP, et al. Biomed Res Int. 2015;2015:538019. doi: 10.1155/2015/538019. Epub 2015 Mar 19. Biomed Res Int. 2015. PMID: 25866791 Free PMC article. Review. - IGFBPs and neoplastic models. New concepts for roles of IGFBPs in regulation of cancer cell growth.
Oh Y. Oh Y. Endocrine. 1997 Aug;7(1):111-3. doi: 10.1007/BF02778076. Endocrine. 1997. PMID: 9449045 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources